Publication | Closed Access

Erlotinib Versus Etoposide/Cisplatin With Radiation Therapy in Unresectable Stage III Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter, Randomized, Open-Label, Phase 2 Trial

Radiation MedicineRadiation TherapyMedicinePathologyErlotinib Versus Etoposide/cisplatinCancer TreatmentCancer GeneticsPhase 2OncologyRadiation OncologyLung CancerMolecular Oncology